Perspectives on Life Sciences
315 total results. Page 1 of 13.
The top legal issues in 2024 for the life sciences field reflect the complex and changing legal landscape that the industry is navigating, encompassing drug pricing, regulatory challenges, and broader societal and governance concerns.
A major new research paper has concluded what many doctors had long believed was true – that patients can be switched between reference (or name brand) biologics and biosimilars with no issues involving the safety profiles or immunogenicity rates of the two drugs.
Artificial intelligence promises to transform the way we live and work and its impact will undoubtedly stretch to every business sector across the globe. This next generation of technology brings exciting possibilities and unknown legal risks.
Artificial intelligence (AI) is rapidly transforming the life sciences industry, with significant advancements in various areas. These innovations bring new legal challenges related to intellectual property, data protection, regulatory compliance, and ethical considerations.
ArentFox Schiff is pleased to announce that the firm and three partners have been shortlisted for the annual LMG Life Sciences Americas Awards.
ArentFox Schiff is pleased to announce that 93 attorneys and 21 practices have been ranked by The Legal 500 United States 2023 guide, a nationwide analysis of law firms that provide cutting-edge and innovative advice.
For decades, the Securities and Exchange Commission (SEC) and criminal prosecutors have pursued claims for insider trading in securities by persons who learn material nonpublic information about clinical drug trials.
Partner Andy Sawula and Associate Sam Rasche discuss how to respond to EPA Information Requests.
ArentFox Schiff represented NorthView Acquisition Corp., a publicly traded special purpose acquisition company, in its merger with Profusa, Inc., a digital health company.
We represented NextPlat Corp., a global e-commerce platform company, in its strategic investments in Progressive Care Inc., a personalized healthcare services and technology company.
ArentFox Schiff advised GBS Inc. (Nasdaq: GBS) on its acquisition of Intelligent Fingerprinting Limited, including its proprietary drugs of abuse screening technology.
Byron Dorgan*, Doug Jones*, Philip S. English*, Dan H. Renberg, Jon S. Bouker, Craig Engle, David P. Grosso, Cissy Jackson, Oliver Spurgeon III*, Amy Antoniolli, Stephen P. Hanson, Laura E. Doyle*, Jeri Freirich*, Daniel Sjostedt*
Americans woke up on Wednesday, November 9, immediately realizing something was different. On their televisions and other devices, they only saw commercials for products, vacation spots, and reality shows.
We represented Boustead Securities, LLC as the sole underwriter in Know Labs, Inc.’s $8.28 million public offering of common stock.
ArentFox Schiff secured an important victory for Azurity Pharmaceuticals, Inc. when the US Court of Appeals for the First Circuit found that the Food, Drug, and Cosmetic Act permits a pharmaceutical company to pursue false advertising claims against a compounding pharmacy, Edge Pharma, LLC.
The Metaverse stands to disrupt nearly every industry – fashion, media and entertainment, real estate, sports, the list goes on – presenting immense possibilities and potential risks. We have created the ArentFox Schiff Industry Guide to the Metaverse to answer questions and anticipate concerns.
ArentFox Schiff is pleased to announce that the firm and two partners have been shortlisted for the annual LMG Life Sciences Americas Awards.
Attorney-Client Privilege Issues: Three Ways Companies Can Shield Privileged Communications From Their Directors
Directors owe fiduciary duties to the company. To make informed decisions and satisfy those fiduciary duties, directors generally have broad access to the company’s books and records, with a few exceptions.